RXi
RXi Posts Flat Q3 Net Loss
Premium
NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.
RXi Q2 Losses Hold Steady
Premium
NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.
NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has started a third Phase IIa trial for its anti-scarring treatment RXI-109.
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
RXi Pharmaceuticals has appointed Peter Campochiaro to its scientific advisory board.
May 15, 2014
May 8, 2014
May 1, 2014
Apr 24, 2014
Apr 24, 2014
Feb 20, 2014
RXi Regains Nasdaq Listing
Premium
Dec 19, 2013
Nov 21, 2013
Nov 14, 2013
Aug 15, 2013
Aug 8, 2013
Jul 25, 2013
Jul 18, 2013
Jun 27, 2013
Jun 13, 2013
Jun 6, 2013
May 16, 2013
Apr 25, 2013
Apr 4, 2013
Mar 7, 2013